Children born SGA receiving growth hormone have similarly impaired glucose-insulin metabolism as children with obesity - Takeaways - MDSpire

Children born SGA receiving growth hormone have similarly impaired glucose-insulin metabolism as children with obesity

  • By

  • Lea Prengemann

  • Robert Stein

  • Ruth Gausche

  • Christoph Beger

  • Mandy Vogel

  • Eric Wenzel

  • Anette Stoltze

  • Wieland Kiess

  • Roland Pfäffle

  • Antje Körner

  • February 10, 2026

  • 0 min

Share

  • 1

    Children born small for gestational age (SGA) show impaired glucose-insulin metabolism, particularly when treated with growth hormone (GH).

  • 2

    SGA patients receiving GH therapy exhibit higher insulin resistance compared to those with isolated growth hormone deficiency (iGHD).

  • 3

    The prevalence of prediabetes is significantly higher in SGA-GHT children (11.11%) compared to iGHD (1.59%) and obesity (3.13%) cohorts.

  • 4

    After discontinuing GH therapy, SGA-GHT patients retain elevated markers of prediabetes and insulin resistance similar to children with obesity.

  • 5

    Close metabolic monitoring is recommended for GH-treated SGA patients due to their increased risk of glucose-insulin metabolism disturbances.

Original Source(s)

Children born SGA receiving growth hormone have similarly impaired glucose-insulin metabolism as children with obesity

  • by Lea Prengemann, Robert Stein, Ruth Gausche, Christoph Beger, Mandy Vogel, Eric Wenzel, Anette Stoltze, Wieland Kiess, Roland Pfäffle, Antje Körner

  • February 10, 2026

Related Content

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Side Effects: They Googled It

Patients are mining Reddit and TikTok for symptom intel while you're not — and a small study calls it epistemic injustice. Different knowledge, mutually unrecognized. Maybe ask where they've been reading before you wave it off as anecdote.

After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care